Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., . . . Díaz, L. (2016). Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology, 103, 16–26. https://doi.org/10.1016/j.neuropharm.2015.12.017
Dunn, R. W., Corbett, R., & Fielding, S. (1989). Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. European Journal of Pharmacology, 169(1), 1–10. https://doi.org/10.1016/0014-2999(89)90811-x
Thompson, M., Callaghan, P., Hunt, G., Cornish, J., & McGregor, I. (2007). A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience, 146(2), 509–514. https://doi.org/10.1016/j.neuroscience.2007.02.032
de Boer, S. F., & Koolhaas, J. M. (2005). 5-HT1A and 5-HT1B receptor agonists and aggression: A pharmacological challenge of the serotonin deficiency hypothesis. European Journal of Pharmacology, 526(1–3), 125–139. https://doi.org/10.1016/j.ejphar.2005.09.065
Winstanley, C. A., Theobald, D. E. H., Dalley, J. W., & Robbins, T. W. (2005). Interactions between Serotonin and Dopamine in the Control of Impulsive Choice in Rats: Therapeutic Implications for Impulse Control Disorders. Neuropsychopharmacology, 30(4), 669–682. https://doi.org/10.1038/sj.npp.1300610
Bardin, L., Tarayre, J., Malfetes, N., Koek, W., & Colpaert, F. (2003). Profound, Non-Opioid Analgesia Produced by the High-Efficacy 5-HT1A Agonist F 13640 in the Formalin Model of Tonic Nociceptive Pain. Pharmacology, 67(4), 182–194. https://doi.org/10.1159/000068404
Celada, P., Puig, M., Amargós-Bosch, M., Adell, A., & Artigas, F. (2004). The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. Journal of psychiatry & neuroscience : JPN, 29(4), 252–265. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC446220/
InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Depression: How effective are antidepressants? [Updated 2020 Jun 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK361016/
Dubovicky, M., Belovicova, K., Csatlosova, K., & Bogi, E. (2017). Risks of using SSRI / SNRI antidepressants during pregnancy and lactation. Interdisciplinary toxicology, 10(1), 30–34. https://doi.org/10.1515/intox-2017-0004
Smoller, J. W. (2009). Antidepressant Use and Risk of Incident Cardiovascular Morbidity and Mortality Among Postmenopausal Women in the Women’s Health Initiative Study. Archives of Internal Medicine, 169(22), 2128. https://doi.org/10.1001/archinternmed.2009.436
Gibbons, R. D., Brown, C. H., Hur, K., Marcus, S. M., Bhaumik, D. K., & Mann, J. J. (2007). Relationship Between Antidepressants and Suicide Attempts: An Analysis of the Veterans Health Administration Data Sets. American Journal of Psychiatry, 164(7), 1044–1049. https://doi.org/10.1176/ajp.2007.164.7.1044
Iffland, K., & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2(1), 139–154. https://doi.org/10.1089/can.2016.0034
Greer, G. R., Grob, C. S., & Halberstadt, A. L. (2014). PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program. Journal of Psychoactive Drugs, 46(1), 73–77. https://doi.org/10.1080/02791072.2013.873843
Neumeister, A. (2012). THE ENDOCANNABINOID SYSTEM PROVIDES AN AVENUE FOR EVIDENCE-BASED TREATMENT DEVELOPMENT FOR PTSD. Depression and Anxiety, 30(2), 93–96. https://doi.org/10.1002/da.22031
Campos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., . . . Guimarães, F. S. (2013). The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. International Journal of Neuropsychopharmacology, 16(6), 1407–1419. https://doi.org/10.1017/s1461145712001502
Baycrest Centre for Geriatric Care. (2016, January 21). Chronic stress, anxiety can damage the brain, increase risk of major psychiatric disorders. ScienceDaily. Retrieved October 31, 2021 from www.sciencedaily.com/releases/2016/01/160121121818.htm
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., de Martinis, B. S., Kapczinski, F., . . . Crippa, J. A. S. (2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology, 36(6), 1219–1226. https://doi.org/10.1038/npp.2011.6
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., . . . Hallak, J. E. C. (2010). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 25(1), 121–130. https://doi.org/10.1177/0269881110379283
McPartland, J. M., & Russo, E. B. (2001). Cannabis and Cannabis Extracts. Journal of Cannabis Therapeutics, 1(3–4), 103–132. https://doi.org/10.1300/j175v01n03_08
Russo, E., & Guy, G. W. (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses, 66(2), 234–246. https://doi.org/10.1016/j.mehy.2005.08.026
Wilkinson, J. D., Whalley, B. J., Baker, D., Pryce, G., Constanti, A., Gibbons, S., & Williamson, E. M. (2003). Medicinal cannabis: is Δ9–tetrahydrocannabinol necessary for all its effects? Journal of Pharmacy and Pharmacology, 55(12), 1687–1694. https://doi.org/10.1211/0022357022304
Zgair, A., Wong, J. C., Lee, J. B., Mistry, J., Sivak, O., Wasan, K. M., Hennig, I. M., Barrett, D. A., Constantinescu, C. S., Fischer, P. M., & Gershkovich, P. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American journal of translational research, 8(8), 3448–3459.
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2012). A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. European Journal of Clinical Pharmacology, 69(4), 825–834. https://doi.org/10.1007/s00228-012-1393-4
Marchiori, E., Zanetti, G., Mano, C. M., & Hochhegger, B. (2011). Exogenous lipoid pneumonia. Clinical and radiological manifestations. Respiratory Medicine, 105(5), 659–666. https://doi.org/10.1016/j.rmed.2010.12.001
Shannon, S. (2016). Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. The Permanente Journal, 20(4). https://doi.org/10.7812/tpp/16-005
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry, 41(1), 9–14. https://doi.org/10.1590/1516-4446-2017-0015
